---
title: "XIHARI released its performance for the first half of the year, with a net profit attributable to the parent company of 133 million yuan, an increase of 14.09%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253780109.md"
description: "XIHARI released its 2025 semi-annual report, with operating revenue of 420 million yuan, a year-on-year increase of 11.57%; net profit attributable to shareholders of 133 million yuan, a year-on-year increase of 14.09%; net profit excluding non-recurring gains and losses of 123 million yuan, a year-on-year increase of 37.59%. The basic earnings per share is 0.4192 yuan, and it plans to distribute a cash dividend of 2.31 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-08-20T09:38:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253780109.md)
  - [en](https://longbridge.com/en/news/253780109.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253780109.md)
generator: "portal-rs"
---

# XIHARI released its performance for the first half of the year, with a net profit attributable to the parent company of 133 million yuan, an increase of 14.09%

According to the Zhitong Finance APP, XIHARI (688334.SH) released its semi-annual report for 2025, with operating revenue of 420 million yuan, a year-on-year increase of 11.57%. The net profit attributable to shareholders of the listed company was 133 million yuan, a year-on-year increase of 14.09%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 123 million yuan, a year-on-year increase of 37.59%. The basic earnings per share were 0.4192 yuan. In addition, it plans to distribute a cash dividend of 2.31 yuan (tax included) for every 10 shares to all shareholders

### Related Stocks

- [688334.CN](https://longbridge.com/en/quote/688334.CN.md)

## Related News & Research

- [LIVE MARKETS-Europe's time to shine?](https://longbridge.com/en/news/296085944.md)
- [PFSE: Record Q2 revenue and profit growth, driven by strong demand and innovation in HVDC technology](https://longbridge.com/en/news/296308264.md)
- [Dicot Pharma submits EU clinical trial application for LIB-01 phase 2b study](https://longbridge.com/en/news/296068059.md)
- [JIC Venture Growth Investments takes minority stake in BiPSEE via Venture Growth Fund 2](https://longbridge.com/en/news/296036524.md)
- [€1.50: That's What Analysts Think Kamux Oyj (HEL:KAMUX) Is Worth After Its Latest Results](https://longbridge.com/en/news/296052386.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**